Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI scores Niki Biosolutions, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Niki Biosolutions, Inc. is a small-cap company with a market capitalization of $5M. It ranks number 11 by market capitalization among the 11 Measuring & Controlling Devices, NEC issuers in our coverage with a current forecast. Its P/B Ratio of 0.21x is the lowest of the 11 peers that report one.
For NIKI, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NIKI included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Measuring & Controlling Devices, NEC peers listed below that report each metric.
| Metric | NIKI | Rank |
|---|---|---|
| Market Cap | $5M | 11/11 |
| P/B Ratio | 0.21x | 11/11 |
| Book Value/Share | $7.02 | – |
| Metric | NIKI | Rank |
|---|---|---|
| D/E Ratio | 0.21x | 9/11 |
| Financial Leverage | 0.81x | 11/11 |
| Metric | NIKI | Rank |
|---|---|---|
| Shares Outstanding | 3M | – |
| Accounts Receivable | $110K | 0.4% of assets |
| Total Liabilities | $5M | 17.2% of assets |
Companies classified under the same SEC industry code as Niki Biosolutions, Inc. (Measuring & Controlling Devices, NEC): 11 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| NIKI Niki Biosolutions, Inc. | $5M | |
| TMO Thermo Fisher Scientific Inc. | $250.82B | |
| ROK Rockwell Automation, Inc | $41.74B | |
| TRMB Trimble Inc. | $12.51B | |
| ONTO Onto Innovation Inc. | $8.50B | |
| MIR Mirion Technologies, Inc. | $4.48B | |
| QSI Quantum-Si Inc | $287M | |
| OWLT Owlet, Inc. | $124M | |
| GEOS Geospace Technologies Corp | $49M | |
| AATC Autoscope Technologies Corp | $32M | |
| BCHT Birchtech Corp. | $27M |
Company’s blood-based microRNA biomarker panel is designed to support monitoring of disease progression and treatment response in Rett syndrome. Access the “Rett Research Tool ...
NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research useNEW HAVEN, CT ...
PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE)-- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs through ...
Our AI scores Niki Biosolutions, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For NIKI, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Niki Biosolutions, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
11 issuers in our coverage, NIKI included, share the SEC industry code Measuring & Controlling Devices, NEC. The largest are: Thermo Fisher Scientific Inc. (TMO), Rockwell Automation, Inc (ROK), Trimble Inc. (TRMB), Onto Innovation Inc. (ONTO), Mirion Technologies, Inc. (MIR), Quantum-Si Inc (QSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
